DHI Sponsored Lissitzky Career Award at 2009 European Thyroid Association Annual Meeting
ATHENS, Ohio – Diagnostic Hybrids was the exclusive sponsor of the Emeritus Lissitzky Career Award at the 34th Annual Meeting of the European Thyroid Association in Lisbon, Portugal. The prize is awarded biannually to a distinguished member of the association who has made life-long contributions to the European thyroid research community.
This year, the prize was presented to “well-known thyroid scientist Prof. Gabriela Morreale of Madrid for her excellent long-time achievements,” according to Prof. George J. Kahaly, Treasurer of the European Thyroid Association. Morreale studies the relationship between pregnancy and thyroid function.
The award was presented in a morning ceremony held on Sept. 6 at the University of Lisbon and included a research grant, as well as travel expenses, accommodations, and a medal.
“Diagnostic Hybrids is proud to be a supporter of the European Thyroid Association and its leadership in furthering thyroid research in Europe and across the globe,” said Jeff Houtz, Senior Product Manager for Diagnostic Hybrids’ thyroid testing products. “Sponsorship of this award represents our appreciation for the organization’s efforts and our hope for continued successful collaboration with its members.”
Diagnostic Hybrids recently launched the ThyretainTM TSI Reporter BioAssay, the first FDA-cleared test that specifically detects thyroid stimulating immunoglobulin in patient serum. Thyretain is to be used as an aid in the differential diagnosis of Graves’ disease, an autoimmune thyroid disorder that affects 1-2% of the population1 and can be difficult to diagnose due to nonspecific early symptoms.
The 34th Annual Meeting of the European Thyroid Association was held at the University of Lisbon’s Aula Magna from Sept. 5 to Sept. 9, 2009. For more information, visit www.eta09.com.
About Diagnostic Hybrids
Diagnostic Hybrids invents, develops, manufactures, and sells innovative diagnostic and analytical products for a wide range of viral respiratory diseases, herpes virus infections, and other specific viral and thyroid diseases. The company also develops and commercializes innovative and genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry, with an initial focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. The company is certified to ISO 13485 standards and manufactures live continuous and primary cell cultures for clinical diagnostics and pharmacology assays from its headquarters in Athens, OH. Diagnostic Hybrids was named one of the 500 Fastest Growing Companies in America in 2004 and 2005 by Inc. Magazine. The company is a pillar member of BioOhio, a statewide organization of bioscience companies accelerating the bioscience and healthcare economy in Ohio. For more information, please visit www.dhiusa.com.
Contact:
Christina Dierkes
Coordinator, Marketing Communications & Public Relations
christina_dierkes@dhiusa.com
p: 740-589-3300
